We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
226
Parallel Advisors
California
– -$76.2K -1,893 Closed
LIM
227
Longfellow Investment Management
Massachusetts
– -$74.8K -1,860 Closed
US Bancorp
228
US Bancorp
Minnesota
– -$55.5K -1,380 Closed
SOW
229
State of Wyoming
Wyoming
– -$51.8K -1,288 Closed
TRCT
230
Tower Research Capital (TRC)
New York
– -$49.1K -1,221 Closed
EWA
231
EverSource Wealth Advisors
Alabama
– -$49K -1,219 Closed
AF
232
Allworth Financial
California
– -$46K -1,143 Closed
BNP Paribas Asset Management
233
BNP Paribas Asset Management
France
– -$44.3K -1,100 Closed
VCM
234
Versant Capital Management
Arizona
– -$42.4K -1,053 Closed
S
235
SignatureFD
Georgia
– -$38.4K -954 Closed
GI
236
GAMMA Investing
California
– -$32K -796 Closed
SCM
237
Sterling Capital Management
North Carolina
– -$31.1K -772 Closed
LSA
238
Leonteq Securities AG
Switzerland
– -$27K -671 Closed
SIS
239
Sound Income Strategies
Florida
– -$25.1K -621 Closed
AIC
240
Archer Investment Corporation
Indiana
– -$20.1K -500 Closed
SS
241
SBI Securities
Japan
– -$10.3K -257 Closed
Nisa Investment Advisors
242
Nisa Investment Advisors
Missouri
– -$10.1K -252 Closed
LFG
243
Larson Financial Group
Missouri
– -$10.1K -250 Closed
C
244
Covestor
United Kingdom
– -$9K -228 Closed
QC
245
Quent Capital
New York
– -$8.73K -217 Closed
TFM
246
TFC Financial Management
Massachusetts
– -$8.53K -212 Closed
HPC
247
HM Payson & Co
Maine
– -$8.05K -200 Closed
UB
248
UMB Bank
Missouri
– -$7.8K -194 Closed
PWPS
249
Pinnacle Wealth Planning Services
Ohio
– -$7.72K -192 Closed
MCM
250
MAI Capital Management
Ohio
– -$4.47K -111 Closed
8 9
10
11 12

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.